Market Place
Sourcing Support
Sensei lays off 46% of staff, closes site to fund cancer trial
14 Nov 2024 //
FIERCE BIOTECH
Sensei Bio Reports Q3 2024 Financial Results & Highlights
14 Nov 2024 //
GLOBENEWSWIRE
Sensei Biotherapeutics to Present at Two Upcoming Conferences
29 Oct 2024 //
GLOBENEWSWIRE
Sensei Biotherapeutics to Present at Upcoming Conferences
04 Sep 2024 //
GLOBENEWSWIRE
Sensei Biotherapeutics To Present SNS-103 Data At Conference
04 Sep 2024 //
GLOBENEWSWIRE
Sensei Biotherapeutics Reports Q2 2024 Results And Business Highlights
06 Aug 2024 //
GLOBENEWSWIRE
Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference
30 May 2024 //
GLOBENEWSWIRE
Sensei Bio Phase 1 Promising: Sns-101 Dose Escalation Data Shown
23 May 2024 //
GLOBENEWSWIRE
Sensei Bio Q1 2024 Financials And Business Highlights
09 May 2024 //
GLOBENEWSWIRE
Sensei to Present SNS-101 Phase 1 Topline Data at ASCO 2024
24 Apr 2024 //
GLOBENEWSWIRE
Sensei Biotherapeutics Attends Oncology Conference
09 Apr 2024 //
GLOBENEWSWIRE
Sensei Announces Nature Communi Describing MOA of SNS-101 Selectively Targeting
04 Apr 2024 //
GLOBENEWSWIRE
Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium
22 Mar 2024 //
GLOBENEWSWIRE
Sensei to Present New Preclinical Data at Upcoming Scientific Conferences
06 Mar 2024 //
GLOBENEWSWIRE
Sensei Reports Full Year 2023 Financial Results and Recent Business Highlights
28 Feb 2024 //
GLOBENEWSWIRE
Sensei Biotherapeutics to Present at Upcoming Conferences
07 Feb 2024 //
GLOBENEWSWIRE
Sensei Provides Corporate Update and Highlights Key Upcoming Milestones
04 Jan 2024 //
GLOBENEWSWIRE
Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results
07 Nov 2023 //
GLOBENEWSWIRE
Sensei Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting
03 Nov 2023 //
GLOBENEWSWIRE
Sensei Bio Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer
01 Nov 2023 //
GLOBENEWSWIRE
Sensei Biotherapeutics to Present Data from Dose Escalation Trial of SNS-101
25 Oct 2023 //
GLOBENEWSWIRE
Sensei Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101
23 Oct 2023 //
GLOBENEWSWIRE
Sensei Announces Initiation of Combination Arm for Phase 1/2 Study of SNS-101
27 Sep 2023 //
GLOBENEWSWIRE
Sensei Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile
21 Sep 2023 //
GLOBENEWSWIRE
Sensei Biotherapeutics to Participate in Upcoming Investor Conferences
30 Aug 2023 //
GLOBENEWSWIRE
Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results
03 Aug 2023 //
GLOBENEWSWIRE
Sensei to Participate in Canaccord Genuity`s 43rd Annual Growth Conference
02 Aug 2023 //
GLOBENEWSWIRE
Sensei to Host Virtual Key Opinion Leader Event, A New Vista for Cancer Care
13 Jun 2023 //
GLOBENEWSWIRE
Sensei Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101
01 Jun 2023 //
GLOBENEWSWIRE
Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference
31 May 2023 //
GLOBENEWSWIRE
Sensei Biotherapeutics Reports1Q 2023 FYR and Recent Business Highlights
09 May 2023 //
GLOBENEWSWIRE
Sensei Announces IND Clearance by U.S. FDA Enabling Ph1 Initiation for SNS-101
20 Apr 2023 //
GLOBENEWSWIRE
Sensei Biotherapeutics Presents New Preclinical Data on SNS-103
18 Apr 2023 //
GLOBENEWSWIRE
Sensei to Participate in Canaccord Genuity Horizons in Oncology Conference
13 Apr 2023 //
GLOBENEWSWIRE
Sensei to Participate in Cantor Fitzgerald Future of Oncology Virtual Symposium
30 Mar 2023 //
GLOBENEWSWIRE
Sensei Reports Full Year 2022 Financial Results and Recent Business Highlights
28 Mar 2023 //
GLOBENEWSWIRE
Sensei Biotherapeutics Announces Submission of IND Application for SNS-101
21 Mar 2023 //
GLOBENEWSWIRE
Sensei Biotherapeutics to Present New Preclinical Data for SNS-103
14 Mar 2023 //
GLOBENEWSWIRE
Sensei Biotherapeutics Adopts Stockholder Rights Agreement
07 Mar 2023 //
GLOBENEWSWIRE
Sensei to Participate in Oppenheimer`s 33rd Annual Healthcare Conference
06 Mar 2023 //
GLOBENEWSWIRE
Sensei Biotherapeutics Presents Preclinical Data for SNS-101
21 Feb 2023 //
GLOBENEWSWIRE
Sensei to Participate in Citi 2023 Virtual Oncology Leadership Summit
16 Feb 2023 //
GLOBENEWSWIRE
Sensei to Present Data for SNS-101,Conditionally Active VISTA-blocking Antibody
14 Feb 2023 //
GLOBENEWSWIRE
Sensei Bio Signs CRADA with the NCI to Develop Plan for SNS-101
06 Feb 2023 //
GLOBENEWSWIRE
Sensei Biotherapeutics Announces Clinical Supply Agreement with Regeneron
05 Jan 2023 //
GLOBENEWSWIRE
Sensei Biotherapeutics Provides Update on Strategic Priorities
08 Dec 2022 //
GLOBENEWSWIRE
Sensei to Participate in the Piper Sandler 34th Annual Healthcare Conference
22 Nov 2022 //
GLOBENEWSWIRE
Sensei Biotherapeutics Announces Collaboration with Washington University
21 Nov 2022 //
GLOBENEWSWIRE
Sensei Biotherapeutics to Present New Preclinical Data at the (SITC)
05 Oct 2022 //
GLOBENEWSWIRE
Sensei Biotherapeutics Presents Preclinical Data for SNS-101
30 Sep 2022 //
GLOBENEWSWIRE
Sensei Biotherapeutics to Present Preclinical Data for SNS-101 Survival
21 Sep 2022 //
GLOBENEWSWIRE
Sensei Biotherapeutics Announces New Preclinical Data Demonstrating Favorable
31 Aug 2022 //
GLOBENEWSWIRE
Sensei Biotherapeutics to Participate in Upcoming Investor Conferences
23 Aug 2022 //
GLOBENEWSWIRE
Sensei Biotherapeutics Reports Second Quarter 2022 Financial Results
09 Aug 2022 //
GLOBENEWSWIRE
Sensei Biotherapeutics Appoints Patrick Gallagher, MBA, MPH, as CBO
01 Jun 2022 //
GLOBENEWSWIRE
Sensei Biotherapeutics to Participate in Jefferies Healthcare Conference
25 May 2022 //
GLOBENEWSWIRE
Sensei Biotherapeutics Reports First Quarter 2022 Financial Results
10 May 2022 //
GLOBENEWSWIRE
Sensei BioTx Reports FY 2021 Financial Results
10 Mar 2022 //
GLOBENEWSWIRE
Sensei Bio Appoints William Ringo, MBA, as Chair of Board of Directors
09 Mar 2022 //
GLOBENEWSWIRE
